JP2017536558A5 - - Google Patents

Info

Publication number

JP2017536558A5

JP2017536558A5 JP2017546035A JP2017546035A JP2017536558A5 JP 2017536558 A5 JP2017536558 A5 JP 2017536558A5 JP 2017546035 A JP2017546035 A JP 2017546035A JP 2017546035 A JP2017546035 A JP 2017546035A JP 2017536558 A5 JP2017536558 A5 JP 2017536558A5

Authority

JP

Japan

Prior art keywords

expression

subject

egf

mcp1

ngal

Prior art date

2015-11-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims 15
• 239000000090 biomarker Substances 0.000 claims 11
• 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 7
• 102000000018 Chemokine CCL2 Human genes 0.000 claims 7
• 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 7
• 101800004564 Transforming growth factor alpha Proteins 0.000 claims 7
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 6
• 101800003838 Epidermal growth factor Proteins 0.000 claims 5
• 102100033237 Pro-epidermal growth factor Human genes 0.000 claims 5
• 229940116977 epidermal growth factor Drugs 0.000 claims 5
• 239000012472 biological sample Substances 0.000 claims 4
• 208000020832 chronic kidney disease Diseases 0.000 claims 4
• 238000011156 evaluation Methods 0.000 claims 3
• 238000003018 immunoassay Methods 0.000 claims 3
• 102000030914 Fatty Acid-Binding Human genes 0.000 claims 2
• 102000013382 Gelatinases Human genes 0.000 claims 2
• 108010026132 Gelatinases Proteins 0.000 claims 2
• 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 2
• 102000004889 Interleukin-6 Human genes 0.000 claims 2
• 108090001005 Interleukin-6 Proteins 0.000 claims 2
• 102000004058 Leukemia inhibitory factor Human genes 0.000 claims 2
• 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 2
• 102000019298 Lipocalin Human genes 0.000 claims 2
• 108050006654 Lipocalin Proteins 0.000 claims 2
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 2
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 108091022862 fatty acid binding Proteins 0.000 claims 2
• 238000000338 in vitro Methods 0.000 claims 2
• 229940100601 interleukin-6 Drugs 0.000 claims 2
• 210000000440 neutrophil Anatomy 0.000 claims 2
• 102000004169 proteins and genes Human genes 0.000 claims 2
• 108090000623 proteins and genes Proteins 0.000 claims 2
• 229940124597 therapeutic agent Drugs 0.000 claims 2
• NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 1
• KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 1
• 102000012192 Cystatin C Human genes 0.000 claims 1
• 108010061642 Cystatin C Proteins 0.000 claims 1
• 102100037362 Fibronectin Human genes 0.000 claims 1
• 108010067306 Fibronectins Proteins 0.000 claims 1
• 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 1
• 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims 1
• 102000013519 Lipocalin-2 Human genes 0.000 claims 1
• 108010051335 Lipocalin-2 Proteins 0.000 claims 1
• 102000004264 Osteopontin Human genes 0.000 claims 1
• 108010081689 Osteopontin Proteins 0.000 claims 1
• 206010061481 Renal injury Diseases 0.000 claims 1
• 102100040613 Uromodulin Human genes 0.000 claims 1
• 108010027007 Uromodulin Proteins 0.000 claims 1
• 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
• 230000003247 decreasing effect Effects 0.000 claims 1
• 230000004069 differentiation Effects 0.000 claims 1
• 230000024924 glomerular filtration Effects 0.000 claims 1
• 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
• 238000012544 monitoring process Methods 0.000 claims 1
• 239000000523 sample Substances 0.000 claims 1
• 210000002966 serum Anatomy 0.000 claims 1
• 210000002700 urine Anatomy 0.000 claims 1